Published in Physician Business Week, January 16th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Novartis.
Report 1: Zelnorm (tegaserod maleate) has demonstrated potential to treat the multiple symptoms of dysmotility-type dyspepsia.
"These multiple symptoms have a very significant impact on patients' lives," said Loren Laine, MD professor of Medicine, University of Southern California School of Medicine. "For patients with moderate to severe symptoms the results of these studies are promising and suggest a benefit for tegaserod."
Pooled data from two...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.